van Kempen ZLE, Hogenboom L, Toorop AA, Steenhuis M, et al. Ocrelizumab concentration is a good predictor of SARS-CoV-2 vaccination response in patients with multiple sclerosis. Ann Neurol 2022 Oct 17. doi: 10.1002/ana.26534.
PMID: 36250739